相关实验视频
Updated: Jul 21, 2025

09:28
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
Published on: November 25, 2014
18.9K
神经血管传播的血清能调节:专注于前置的5-HT受体/机制
Abimael González-Hernández1, Bruno A Marichal-Cancino2, Antoinette MaassenVanDenBrink3
1Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Queretaro 76230, Mexico.
Biomedicines
|July 29, 2023
概括
血素 (5-基三胺或5-HT) 对血压有复杂的影响,通过前节受体影响神经递质的释放. 它的确切影响取决于被激活的特定受体,导致高血压或低血压的结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
背景情况:
- 5-基三胺 (5-HT),也称为血清素,是关键的神经调节剂和神经递质.
- 5-HT通过各种受体亚型产生多样化的作用,包括metabotropic (与G蛋白结合) 和ionotropic受体.
- 它在血压调节中的作用涉及中央和外围的作用,影响血管光滑肌肉,内皮和神经功能.
研究的目的:
- 审查和讨论5-HT在血压调节中的预结机制.
- 阐明5-HT对神经递质释放及其对血压的后续影响的复杂影响.
- 探索5-HT在血管相关疾病中的预结作用的含义.
主要方法:
- 文献综述和现有关于5-HT在心血管调节中的作用研究的综合.
- 对研究5-HT受体亚型及其信号通路的研究分析.
- 检查关于5-HT对自主和感官神经递质释放的影响的证据.
主要成果:
- 5-HT对血压的影响取决于情境,由自主神经和感官神经上的前结受体介导.
- 不同的5-HT前结受体的激活可以促进或抑制神经递质的释放,如诺拉丁上腺素,乙胆和CGRP.
- 这种差异性神经递质释放导致高血压或低血压的影响,突出显示了5-HT心血管作用的复杂性.
结论:
- 5-HT的前结机制显著影响血压调节.
- 5-HT对血压的净影响是由被激活的特定预结受体亚型及其下游信号决定的.
- 了解这些机制对于理解5-HT在血管疾病中的作用以及潜在的治疗干预至关重要.
相关概念视频
Neurochemical Transmission: Sites of Drug Action
2.5K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.5K
Cholinergic Neurons: Neurotransmission
3.1K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
3.1K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
310
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
310
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Adrenergic Neurons: Neurotransmission
3.9K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346

